Nivolumab Wins First-Line Indication in Metastatic UC Nivolumab Wins First-Line Indication in Metastatic UC

The FDA approved nivolumab alongside cisplatin and gemcitabine in the frontline for adults with unresectable or metastatic disease.Medscape Medical News
Source: Medscape Urology Headlines - Category: Urology & Nephrology Tags: Hematology-Oncology Source Type: news